期刊文献+

HPLC法测定大鼠肝微粒体中睾酮的含量 被引量:3

Content Determination of Testosterone in Rat Liver Microsomes by HPLC
原文传递
导出
摘要 目的:建立以高效液相色谱法测定大鼠肝微粒体中细胞色素P4503A4(CYP3A4)探针底物睾酮含量的方法。方法:色谱柱为Ultimate-XB C18,流动相为水-乙腈(50∶50),内标为地西泮,流速为1.0mL·min-1,检测波长为245nm,柱温为30℃,进样量为20μL。结果:睾酮生物样品检测浓度的线性范围为10.0~200.0μmo·lL-1(r=0.9995);低、中、高浓度的平均方法回收率分别为86.15%、103.10%、97.48%,平均相对回收率为111.15%、107.24%、100.78%,日内RSD分别为3.92%、2.46%、2.82%,日间RSD分别为2.98%、1.34%、2.41%。结论:本方法简便快速、灵敏度高、重复性好,可用于大鼠肝微粒体中CYP3A4活性的测定及相关研究应用。 OBJECTIVE: To develop a HPLC method for the content determination of cytochrome P450 3A4 (CYP3A4) probe substrate testosterone in rat liver microsomes. METHODS: The determination was performed on Ultimate-XB C18 column with mobile phase consisted of water-acetonitrile (50 ∶ 50, V/V) using diazepam as internal standard at flow rate of 1.0 mL·min-1. The detection wavelength was set at 245 nm and the column temperature was 30 ℃. The injection volume was 20 μL. RESULTS: The liner range of testosterone was 10.0~200.0 μmol·L-1 (r=0.999 5); The average method recovery rates of testosterone with low, medium and high concentration were 86.15%, 103.10% and 97.48%. The average relative recovery rates of three concentrations were 111.15%, 107.24% and 100.78%.The intra-day RSD were 3.92%, 2.46% and 2.82% and the inter-day RSD were 2.98%, 1.34% and 2.41%, respectively. CONCLUSION: The method is simple, convenient, sensitive and reproducible for the determination of CYP3A4 activity and other fields.
出处 《中国药房》 CAS CSCD 北大核心 2010年第37期3482-3484,共3页 China Pharmacy
关键词 睾酮 细胞色素P4503A4 大鼠 肝微粒体 含量 高效液相色谱法 Testosterone Cytochrome P450 3A4 Rat Liver microsomes Content HPLC
  • 相关文献

参考文献9

  • 1Nelson DR, Kamataki T, Waxman D J, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature[J]. DNA Cell Biol, 1993, 12( 1 ) : 1.
  • 2Imaoka ST, Yamada T, Hiroi K, et al. Muitiple forms of human P450 expressed in saccharomyces cerevisiae, systematic characterization and comparison with those of the rat[J]. Biochem Pharmacol, 1996,51 (8):1 041.
  • 3Yamano S, Tatsuno J, Gonzale FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes[J]. Biochemistry, 1990,29(5):1 322.
  • 4Caroline AL, Sue HK, Thomas AK, et al. CYP3A4 expressed by insect cells infected with a recombinant baculovirus bontaining both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4[J]. Archives of Biochemistry and Biophysics, 1995,319 (1):157.
  • 5Arthur GR, William MA. Energetics of heterotropic cooperativity between a-naphthoflavone and testosterone binding to CYP3A4[J]. Archives of Biochemistry and Biophysics, 2007,463(1) : 89.
  • 6张荣,刘昌辉,王宁生,宓穗卿.以睾酮为探针采用高效液相色谱法测定细胞色素CYP450 3A4的酶活性[J].色谱,2008,26(1):80-83. 被引量:19
  • 7Jessica LF, David MP, Barbara JR, et al. A novel testosterone 6b-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro[J]. J Pharmacol Toxicol Methods, 2002, 46 (2) : 117.
  • 8张石革.若干处方药撤出市场的回顾与思考[J].药物不良反应杂志,2002,4(1):14-19. 被引量:2
  • 9Rile RJ, Howbrook D. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin[J]. J Pharmacol Toxicol Methods, 1997,38(4) : 189.

二级参考文献48

  • 1邱立民.特非那丁心脏毒问题[J].实用医学杂志,1996,12(1):53-55. 被引量:6
  • 2朱珠 孙忠实.阿洛司琼上市9个月即撤出市场[J].中国药学杂志,2001,36(3):211-211.
  • 3刘晓梅 邓杨梅.英国和法国分别禁用和限用西沙必利[J].国外医学:药学分册,2001,28(1):64-64.
  • 4FDA.Explains withdrawn of antiobesity drugs.Scrip,1997,(2270):20.
  • 5Hey JA, Del Prado M, Sherwood J, et al.Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung, 1996,46: 315.
  • 6刘兆英 罗延宏 王应忠.特非那定致尖端扭转型室性心动过速1例[J].临床心血管病杂志,1999,15(1):20-20.
  • 7黄建明.特非那定致阵发性心动过速2例报告[J].新医学杂志,1999,30(3):115-115.
  • 8Mulfins ME, Horowitz BZ, Linden DH, et al. Life - threatening interaction of mibefradil and β - blockers with dihydropyridine calcium channel blockers. JAMA, 1998, 280:157.
  • 9Bischoff H.New Pharmacological approaches totherapy of NIDDM.EurJClin Invest,1994,24(Suppl3):28.
  • 10Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology, 2001, 120:557.

共引文献19

同被引文献22

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部